Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy

被引：22

作者：

Dal Molin, Graziela Z. ^{[1
]}

Omatsu, Kohei ^{[2
]}

Sood, Anil K. ^{[1
]}

Coleman, Robert L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1155 Herman Pressler Dr,CPB 6-3590, Houston, TX 77030 USA

[2] Canc Inst Hosp, Dept Gynecol, Tokyo, Japan

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷

关键词：

BRCA; ovarian cancer; PARP; PARP inhibitors; platinum-sensitive ovarian cancer; rucaparib; Rubraca; RECURRENT EPITHELIAL OVARIAN; RIBOSE POLYMERASE INHIBITOR; PARP INHIBITOR; FALLOPIAN-TUBE; DOUBLE-BLIND; OPEN-LABEL; MAINTENANCE THERAPY; PRIMARY PERITONEAL; BRCA2; MUTATIONS; SEROUS OVARIAN;

D O I：

10.1177/1758835918778483

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic) and with homologous recombination deficiency (HRD). Rucaparib as a maintenance treatment showed increased progression-free survival in patients with ovarian carcinoma who achieved a response to platinum-based chemotherapy, with an acceptable safety profile. The approval of this drug, along with the companion diagnostic FoundationFocus CDxBRCA test represents an important new therapeutic option in the treatment of ovarian cancer. This article reviews the mechanisms of action, safety, pharmacokinetics and pharmacodynamics and indications for use of rucaparib as well as future trials.

引用

页数：13

共 50 条

[41] Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy
Fujiwara, Keiichi
Hasegawa, Kosei
Nagao, Shoji
CANCER, 2019, 125 : 4582 - 4586
[42] Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
Tate, Shinichi
Nishikimi, Kyoko
Matsuoka, Ayumu
Otsuka, Satoyo
Shozu, Makio
CANCERS, 2021, 13 (04) : 1 - 11
[43] The Evolving Arena of Ovarian Cancer Maintenance Therapy
Markman, Maurie
ONCOLOGY, 2019, 97 (04) : 202 - 205
[44] Consolidation Therapy in Ovarian Cancer A Clinical Update
Sabbatini, Paul
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 : S35 - S39
[45] The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer
Wallace, Katrine
Adamski, Kelly
Pai, Ashwini
Rose, Darya
Chawla, Anita
PHARMACOECONOMICS, 2021, 39 (02) : 231 - 241
[46] Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer
Guy, Holly
Hawkes, Carol
Walder, Lydia
Malinowska, Izabela A.
Gupta, Divya
FUTURE ONCOLOGY, 2022, 18 (30) : 3435 - 3447
[47] Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer
Moore, Donald C.
Ringley, J. Tanner
Patel, Jolly
JOURNAL OF PHARMACY PRACTICE, 2019, 32 (02) : 219 - 224
[48] Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
Huang, Xuan-zhang
Jia, Han
Xiao, Qiong
Li, Run-zhou
Wang, Xing-shuang
Yin, Hai-yan
Zhou, Xin
FRONTIERS IN ONCOLOGY, 2020, 10
[49] DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
Stefanou, Dimitra T.
Souliotis, Vassilis L.
Zakopoulou, Roubini
Liontos, Michalis
Bamias, Aristotelis
BIOMEDICINES, 2022, 10 (01)
[50] Targeted therapy of ovarian cancer
Volkmer, Anne Kathrin
Fehm, Tanja
Meier, Werner
Ruckhaberle, Eugen
GYNAKOLOGE, 2021, 54 (01): : 55 - 63

← 1 2 3 4 5 →